Roche (OTCMKTS:RHHBY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Genentech Awards Grant to Support Science Center's Translation Project
SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal [Yahoo! Finance]
Pharmaceutical Contract Development and Manufacturing Organization Forecasts Report 2026: A $374.68 Billion Market by 2031 - One-Stop CDMOs, Rapid AI Platforms, and GLP-1/HPAPI Build-Outs Drive Demand [Yahoo! Finance]
Genentech in up to $1.7B RNAi licensing deal with SanegeneBio [Seeking Alpha]